Table 1.

Patient and tumor characteristics at baseline for all eligible patients.

	Bevacizumab + Placebo (n=58)		Bevacizumab + Trebananib (n=57)
Patient or Tumor Characteristic	n	%	n	%
Age (years)
Median	58		57
Min - Max	22 - 79		30 - 80
< 50	17	29.3	14	24.6
≥50	41	70.7	43	75.4
Gender
Male	36	62.1	32	56.1
Female	22	37.9	25	43.9
Race
Asian	2	3.4	0	0.0
Black or African American	3	5.2	2	3.5
White	53	91.4	53	93.0
Unknown or not reported	0	0.0	2	3.5
Ethnicity
Hispanic or Latino	3	5.2	2	3.5
Not Hispanic or Latino	55	94.8	54	94.7
Unknown	0	0.0	1	1.8
Karnofsky Performance Status
70-80	31	53.4	34	59.6
90-100	27	46.6	23	40.4
Neurologic Function
No symptoms	12	20.7	11	19.3
Minor symptoms	32	55.2	27	47.4
Moderate symptoms (fully active)	10	17.2	16	28.1
Moderate symptoms (required assistance)	4	6.9	3	5.3
Surgery (Initial Brain Tumor)
Biopsy only	8	13.8	3	5.3
Subtotal resection	19	32.8	12	21.1
Gross total resection	30	51.7	42	73.7
Other	1	1.7	0	0.0
Recent resection
No/biopsy only	30	51.7	30	52.6
Yes	28	48.3	27	47.4
Histologic Tumor Type
Glioblastoma	53	91.4	53	93.0
Gliosarcoma	2	3.4	2	3.5
Glioblastoma with Oligodendroglial Features	2	3.4	1	1.8
Giant Cell Glioblastoma	0	0.0	1	1.8
Other	1	1.7	0	0.0